Multibagger Selection: Muse Spark 1.1's picks
Muse Spark 1.1 picked MNKD, ABEO, SNDX, MDXG, PACB with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | Muse Spark 1.1 |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | MNKD | — | 72% | — | — |
| 2 | ABEO | — | 68% | — | — |
| 3 | SNDX | — | 70% | — | — |
| 4 | MDXG | — | 65% | — | — |
| 5 | PACB | — | 60% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | -1.58% | -0.79% | 1.13x | 0 |
The model's market view
Small and mid-cap biotech and medtech is in commercial inflection: companies shifting from cash burn to producing revenue, with FDA catalysts in 2026-2027, while large cap faces patent cliffs. Hot CPI and AI unwind punish large growth, creating valuation asymmetry in sub-$2B names with launches, PDUFAs, and gross margin leverage. Liquidity is rising with Russell inclusion and growing analyst coverage.
Why each pick
MNKD
MannKind has commercial base with Afrezza inhaled insulin and V-Go, plus royalties from Tyvaso DPI. Revenue acceleration and margin expansion underway with operating leverage.
ABEO
Abeona launched ZEVASKYN gene therapy with $11.38M Q2 2026 revenue, 5 patients treated Q2 and 12 since launch, showing early commercial traction in RDEB.
SNDX
Syndax has two commercial pillars: Revuforj for KMT2A and expanded mNPM1 AML, and Niktimvo for cGVHD. Revenue growing from low base, consensus $318M 2026 +26% YoY.
MDXG
MiMedx commercial wound care with CHORIOFIX launch March 23 2026, latest addition to placental allografts, 33 hedge fund holders, profitable with growth.
PACB
Pacific Biosciences HiFi long-read sequencing, Nature Methods method of year 2022, revenue $300M addressable $8B open-ended. After 2024-2025 decline, growth inflecting.
Other models on the same run
| Model | Picks |
|---|---|
| GPT-6 | INOD, LUNR, AMPX, RDW, OUST |
| Gemini 2.5 Flash | LUNR, CRMD, FLNC, ACHR, ENVX |
| DeepSeek | INOD, ELVA, MBX, CAPR, KOD |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.